Adam leads TMX Equicom’s Healthcare and Cleantech Group. Since joining the company in 2008, he has provided strategic counsel, high-quality communication programs and relationship capital to public companies spanning a broad range of market capitalizations. He has worked collaboratively with healthcare management teams who have gone through FDA drug approvals, clinical failures, product launches, oversubscribed financings and transactions that haven’t closed. On the cleantech side, among other things, he has worked with management to evaluate M&A opportunities, U.S. listings, and how to effectively manage activist shareholders. Before joining TMX Equicom, he worked for a TSX and AMEX-listed biotechnology company developing a portfolio of cardiovascular drugs. Prior to that, Adam worked for several years as a financial journalist covering public companies on the TSX, NYSE and Nasdaq.